H. Yamada, T. Kameda, Y. Kimura, H. Imai, T. Matsuda, S. Sando, A. Toshimitsu, Y. Aoyama, T. Kondo, *ChemistryOpen* **2016**, *5*, 125.

Multiple‐resonance NMR is a powerful technique,[1](#open201500196-bib-0001){ref-type="ref"}, [2](#open201500196-bib-0002){ref-type="ref"}, [3](#open201500196-bib-0003){ref-type="ref"}, [4](#open201500196-bib-0004){ref-type="ref"} by which particular protons in the sequence ^*1*^ *H*‐^13^C‐^15^N (^1^H‐{^13^C‐^15^N} triple resonance) or ^*1*^ *H*‐^13^C (^1^H‐{^13^C} double resonance) can be detected highly selectively as a result of magnetic coherence transfer ^*1*^ *H*→^13^C→^15^N→^13^C→^*1*^ *H* or ^*1*^ *H*→^13^C→^*1*^ *H*. Although the application of multiple‐resonance NMR (double resonance in many cases,[2](#open201500196-bib-0002){ref-type="ref"}, [3](#open201500196-bib-0003){ref-type="ref"} mostly dealing with main metabolic sources such as glucose, amino acids, and fatty acids, and triple resonance in some[4](#open201500196-bib-0004){ref-type="ref"}) to metabolic analysis is by no means rare, little is known, to the best of our knowledge, about its applicability to hormone‐like trace (μ[m]{.smallcaps}‐level) constituents. In the present work, we applied triple‐resonance NMR to ^13^C/^15^N‐enriched [l]{.smallcaps}‐Dopa ([l]{.smallcaps}‐3,4‐dihydroxyphenylalanine) as the inevitable precursor of neurotransmitter dopamine (2‐(3,4‐dihydroxyphenyl)ethylamine) in the brain.

Dopamine plays important roles in motivation, reward, and motor control,[5](#open201500196-bib-0005){ref-type="ref"} and problems with its metabolism can trigger several neurological/psychological disorders such as Parkinson\'s disease, schizophrenia, and depression.[6](#open201500196-bib-0006){ref-type="ref"}, [7](#open201500196-bib-0007){ref-type="ref"} Scheme [1](#open201500196-fig-5001){ref-type="fig"} summarizes the [l]{.smallcaps}‐Dopa‐to‐dopamine metabolism and its inhibition. The brain is not directly accessible by dopamine, which cannot pass through the blood--brain barrier (BBB). Instead, dopamine is generated in situ in the brain upon decarboxylation of its precursor, [l]{.smallcaps}‐Dopa which is BBB‐permeable, by the enzyme AAAD (aromatic [l]{.smallcaps}‐amino acid decarboxylase). Dopamine thus generated in the brain undergoes rather rapid deactivation upon oxidative deamination by the enzyme MAO (monoamine oxidase, types A and B).

![[l]{.smallcaps}‐Dopa‐to‐dopamine metabolism and its inhibition.](OPEN-5-125-g003){#open201500196-fig-5001}

In clinical practice, [l]{.smallcaps}‐Dopa as the precursor of dopamine is often administered together with inhibitors of enzymes AAAD[8](#open201500196-bib-0008){ref-type="ref"} and MAO‐A and MAO‐B[9](#open201500196-bib-0009){ref-type="ref"} as codrugs to maintain appropriate high concentrations of dopamine in the brain. Another way to achieve high dopamine levels (∼30 μ[m]{.smallcaps} [10](#open201500196-bib-0010){ref-type="ref"}, [11a](#open201500196-bib-0011a){ref-type="ref"}, [11b](#open201500196-bib-0011b){ref-type="ref"} or ∼2 μ[m]{.smallcaps} [11c](#open201500196-bib-0011c){ref-type="ref"})[12](#open201500196-bib-0012){ref-type="ref"} is to electrically stimulate the brain. In this work, we took ^13^C/^15^N‐enriched [l]{.smallcaps}‐Dopa as a triple‐resonance probe to monitor dopamine in mice with a stimulated level of ∼30 μ[m]{.smallcaps} in the brain taken as a criterion to evaluate the performance of the present method. We use the selectivity and sensitivity of triple‐resonance high resolution NMR with a cryogenic probe to perform quantitative metabolic/pharmacokinetic analysis of [l]{.smallcaps}‐Dopa/dopamine in the extracts of brain and liver of mice, showing that the stimulated dopamine level (∼30 μ[m]{.smallcaps}) in the brain can be detected ex vivo. This work also illustrates where we are on the path to direct in vivo MR spectroscopic (MRS) monitoring of this neurotransmitter system.

^13^C/^15^N‐enriched [l]{.smallcaps}‐Dopa (^13^C/^15^N‐[l]{.smallcaps}‐Dopa, Figure [1](#open201500196-fig-0001){ref-type="fig"} a) with a ^1^H‐^13^C‐^15^N sequence involving the asymmetric center was obtained starting from ^13^C/^15^N‐glycine in an optical yield of 94 % *ee*, as detailed in the Supporting Information. ^13^C/^15^N‐enriched dopamine (^13^C/^15^N‐dopamine, Figure [1](#open201500196-fig-0001){ref-type="fig"} b) was also prepared from K^13^C^15^N. One‐dimensional (1D) ^1^H‐{^13^C‐^15^N} triple‐resonance spectra (^13^C‐decoupled) of ^13^C/^15^N‐[l]{.smallcaps}‐Dopa and ^13^C/^15^N‐dopamine showed a single peak at 3.85 ppm or at 3.14 ppm for the methine proton (^**1**^ **H**‐^13^C‐^15^N) of [l]{.smallcaps}‐Dopa or the methylene protons (^**1**^ **H~2~**‐^13^C‐^15^N) of dopamine, respectively. The enzymatic decarboxylation of ^13^C/^15^N‐[l]{.smallcaps}‐Dopa (*δ*=3.85 ppm) to dopamine (*δ*=3.14 ppm) in 4‐(2‐hydroxyethyl)‐1‐piperazineethanesulfonic acid (HEPES) buffer containing the decarboxylation enzyme AAAD was completed in 1 h, as revealed by the triple‐resonance analysis (Figure [1](#open201500196-fig-0001){ref-type="fig"} c) in accord with the results of high‐performance liquid chromatography (HPLC) monitoring (Figure [1](#open201500196-fig-0001){ref-type="fig"} d).

![Structures of a) ^13^C/^15^N‐[l]{.smallcaps}‐Dopa and b) ^13^C/^15^N‐dopamine and analysis of the [l]{.smallcaps}‐Dopa‐to‐dopamine conversion. Time course of the change in c) ^1^H‐{^13^C‐^15^N} NMR spectra and d) HPLC profiles of ^13^C/^15^N‐[l]{.smallcaps}‐Dopa (0.5 m[m]{.smallcaps}) in 40 m[m]{.smallcaps} HEPES containing 80 m[m]{.smallcaps} NaCl, 100 μ[m]{.smallcaps} pyridoxal phosphate, and AAAD (20 ng μ[l]{.smallcaps} ^−1^), incubated at 37 °C for 0 or 60 min. The HPLC trace at the top is for the control run in the absence of AAAD at 60 min. e) Conventional ^1^H (top) and ^1^H‐{^13^C‐^15^N} (bottom) NMR spectra of a mouse liver lysate containing ^13^C/^15^N‐[l]{.smallcaps}‐Dopa (0.5 m[m]{.smallcaps}) in 2 m[m]{.smallcaps} Tris‐HCl, 0.1 m[m]{.smallcaps} EDTA, 0.1 m[m]{.smallcaps} 2‐mercaptoethanol, and 100 μ[m]{.smallcaps} pyridoxal phosphate, incubated at 37 °C for 45 min. f) Inhibitory effects of carbidopa on the decarboxylation of ^13^C/^15^N‐[l]{.smallcaps}‐Dopa. ^1^H‐{^13^C‐^15^N} NMR spectra obtained in the presence of carbidopa (5 or 50 μ[m]{.smallcaps}) as an AAAD inhibitor, under the same conditions as in e). The ^1^H‐{^13^C‐^15^N} NMR spectra were obtained after 256 scans.](OPEN-5-125-g001){#open201500196-fig-0001}

Decarboxylation and its inhibition in complex biological mixtures such as liver lysate could also be readily monitored by triple‐resonance. ^13^C/^15^N‐[l]{.smallcaps}‐Dopa (0.5 m[m]{.smallcaps}) in crude mouse liver lysate was incubated for 45 min. After workup, the mixture was subjected to NMR analysis. The conventional ^1^H NMR spectrum (Figure [1](#open201500196-fig-0001){ref-type="fig"} e, top) was completely useless; all ^1^H‐containing molecules in the lysate represent their signals. The ^1^H‐{^13^C‐^15^N} triple‐resonance spectrum (Figure [1](#open201500196-fig-0001){ref-type="fig"} e, bottom) exhibited two signals at 3.85 ppm for [l]{.smallcaps}‐Dopa and 3.14 ppm for dopamine in a ratio of 1:7 (12 % and 86 % of [l]{.smallcaps}‐Dopa used, respectively), indicating that most of the [l]{.smallcaps}‐Dopa had undergone decarboxylation by endogenous AAAD contained in the liver lysate to give dopamine. In the presence of carbidopa (BBB‐impermeable), a potent AAAD inhibitor that is clinically used as a codrug together with [l]{.smallcaps}‐Dopa (referring to Scheme [1](#open201500196-fig-5001){ref-type="fig"}), the build‐up of dopamine was effectively suppressed (∼85 %) even at \[carbidopa\]=5 μ[m]{.smallcaps} (0.01 equiv of [l]{.smallcaps}‐Dopa (0.5 m[m]{.smallcaps})) (Figure [1](#open201500196-fig-0001){ref-type="fig"} f, bottom) and completely suppressed at \[carbidopa\]=50 μ[m]{.smallcaps} (0.1 equiv) (Figure [1](#open201500196-fig-0001){ref-type="fig"} f, top). Triple resonance can thus completely suppress noise signals arising from endogenous components in complex biological mixtures to allow the unambiguous and quantitative metabolic analyses of ^13^C/^15^N‐enriched substrates therein.

In vitro and ex vivo spectra were obtained with a 700 MHz (16.4 T) NMR spectrometer equipped with a high‐sensitivity cryogenic probe after 256 scans (∼7 min), where the detection limit, i.e., the lowest concentration to give S/N=3, of ^13^C/^15^N‐dopamine lies at around 4 μ[m]{.smallcaps}. Triple‐resonance spectra of ^13^C/^15^N‐dopamine as phantom samples (500 μL) were also obtained with an MR machine for small animals operating at 7 T (300 MHz) without a cryogenic probe (Supporting Information); the detection limit after 3600 scans (1 h) turned out to be ∼1 m[m]{.smallcaps}.

We proceeded to the [l]{.smallcaps}‐Dopa/dopamine metabolic analysis in mice, focusing on the effects of inhibitors of decarboxylation (AAAD) and oxidation (MAO) enzymes. Mice (∼16 g) were administered ^13^C/^15^N‐[l]{.smallcaps}‐Dopa (0.63 mmol kg^−1^) with or without carbidopa (AAAD inhibitor) and MAO inhibitors \[clorgyline and selegiline (BBB‐permeable MAO‐A and MAO‐B inhibitors, respectively; see Scheme [1](#open201500196-fig-5001){ref-type="fig"})\]. After 1 h, brain and liver tissues were collected and, after workup, their triple‐resonance spectra (256 scans) were obtained for doubly diluted (compared with the tissue weights) solutions, as shown in Figure [2](#open201500196-fig-0002){ref-type="fig"}, where the signal intensities for the brain and liver samples are weight‐normalized. In the absence of any inhibitors, a small amount of dopamine (3.14 ppm) was detected in the brain, while a much larger amount was found in the liver (bottom). [l]{.smallcaps}‐Dopa with a signal at 4.19 ppm[13](#open201500196-bib-0013){ref-type="ref"} was hardly detected in the liver or the brain. Most of the [l]{.smallcaps}‐Dopa must have undergone wasteful decarboxylation by endogenous AAAD in the liver, and any dopamine generated remained therein since it could not pass though the BBB to reach the brain. In the presence of the AAAD inhibitor carbidopa (63 μmol kg^−1^), the dopamine level in the brain increased, but only slightly (middle), probably because of its oxidative deamination by MAO to give dopal, which of course exhibited no ^1^H‐^13^C‐^15^N signals. Indeed, when the MAO inhibitors clorgyline (63 μmol kg^−1^) and selegiline (63 μmol kg^−1^) were both present, there was a 5‐fold increase in the dopamine level in the brain, and a substantial amount of [l]{.smallcaps}‐Dopa that escaped decarboxylation remained in the liver (top).[14](#open201500196-bib-0014){ref-type="ref"}, [15](#open201500196-bib-0015){ref-type="ref"} The local concentrations of dopamine in the brain (∼400 mg) were estimated by calibration using an authentic specimen to be 7 μ[m]{.smallcaps} (in the absence of any inhibitors), 15 μ[m]{.smallcaps} (with AAAD inhibitor), and 76 μ[m]{.smallcaps} (with AAAD and MAO inhibitors). The inhibitor‐dependent dopamine levels of 7--76 μ[m]{.smallcaps} are consistent with those of 5--120 μ[m]{.smallcaps} ^[\[]{.smallcaps}9a\]^ reported for rat based on HPLC analysis.

![Effects of MAO inhibitors on the oxidative degradation of ^13^C/^15^N‐dopamine in mice. Weight‐normalized ^1^H‐{^13^C‐^15^N} NMR spectra (256 scans) for the extracts of brain (left) and liver (right) tissues of a mouse coadministered with ^13^C/^15^N‐[l]{.smallcaps}‐Dopa (0.63 mmol kg^−1^) and carbidopa (63 μmol kg^−1^) in the absence (middle) or presence (top) of clorgyline (MAO‐A inhibitor, 63 μmol kg^−1^) and selegiline (MAO‐B inhibitor, 63 μmol kg^−1^). The corresponding spectra in the absence of any inhibitors are shown at the bottom. The tissue extracts obtained were redissolved in D~2~O and subjected to NMR analysis. The in‐brain concentrations of dopamine were quantified via calibration and are shown.](OPEN-5-125-g002){#open201500196-fig-0002}

In this work, we investigated the usefulness of triple resonance for monitoring dopamine at a stimulated ∼30 μ[m]{.smallcaps} level. As shown above, a wide concentration range which includes this critical 30 μ[m]{.smallcaps} could be easily accessed by a combination of [l]{.smallcaps}‐Dopa and inhibitors. Selectivity and sensitivity are key issues in applying NMR to complex biological mixtures. In this context, the present work may be summarized as follows: 1) Triple resonance showed "perfect" selectivity. The probability of the natural occurrence of the sequence ^1^H‐^13^C‐^15^N is as low as 0.011×0.0037=0.00004 (0.004 %), where 0.011 and 0.0037 are the natural abundance of ^13^C and ^15^N, respectively, and the mole‐based selectivity factor for the ^13^C/^15^N‐enriched target over endogenous components is 1/0.00004=25000 (2.5×10^4^). Thus, endogenous components may effectively compete with the enriched target at, for example, 10 μ[m]{.smallcaps}, only when they are present in unnaturally high concentrations of 10×10^4^ μ[m]{.smallcaps}=0.1 [m]{.smallcaps}. An implication of this observation is that selectivity is by no means a formidable issue to deal with for *any* μ[m]{.smallcaps}‐level trace constituents as long as they contain N‐atom(s) and their appropriate double ^13^C/^15^N‐enrichment is synthetically accessible. 2) This perfect, noiseless selectivity of triple resonance gives rise to a μ[m]{.smallcaps} sensitivity \[4 μ[m]{.smallcaps}, 256 scans under less time‐consuming (in minutes), one‐dimensional (monitoring of ^1^H signals only) conditions\]. This allows unambiguous and quantitative ex vivo metabolic/pharmacokinetic analyses of administered [l]{.smallcaps}‐Dopa and its metabolite dopamine, i.e., ratiometric monitoring of their decay/build‐up profiles, which clearly shows that the stimulated level of dopamine in the brain can be monitored ex vivo. 3) Unfortunately, however, the key dopamine level of 30 μ[m]{.smallcaps} is short of the detection limit (∼1 m[m]{.smallcaps}, 3600 scans) of the 7 T MR machine (noncryogenic probe) for noninvasive, i.e., in vivo, monitoring.[16](#open201500196-bib-0016){ref-type="ref"} However, the gap between them is *only* a factor of ∼30. This appears to be significant since an increase in sensitivity of this extent (∼30‐fold) may be achieved by combining an existing highest‐field machine and a high‐sensitivity cryogenic probe equipped with a triple‐resonance coil.[17](#open201500196-bib-0017){ref-type="ref"} In‐brain dopamine may then become a real target of direct in vivo MRS with which we can record the dopamine spectra in the brain.

In addition to a variety of techniques, based on HPLC,[18a](#open201500196-bib-0018a){ref-type="ref"} biological (enzyme‐linked immunosorbent assay, ELISA) affinity (for the analysis of urine),[18b](#open201500196-bib-0018b){ref-type="ref"} microdialysis,[18c](#open201500196-bib-0018c){ref-type="ref"} electrochemical techniques,[18c](#open201500196-bib-0018c){ref-type="ref"} and chemical sensing,[18d](#open201500196-bib-0018d){ref-type="ref"} a couple of methods have recently been developed to monitor dopamine in the brain. One is positron emission tomography (PET) using ^11^C‐raclopride, which competitively binds to the dopamine receptor to enable the \[dopamine\]‐dependent emission of gamma rays.[19](#open201500196-bib-0019){ref-type="ref"} The other is MRI using a protein‐engineered heme‐based contrast agent which reversibly binds to dopamine, thereby changing the relaxivity, and thus gives \[dopamine\]‐dependent images.[10](#open201500196-bib-0010){ref-type="ref"} Both methods are highly sophisticated, but are indirect and involve complicated complexation processes. MRS is much simpler and can directly monitor the targets and their transformations with minimal noise signals which may arise from nonspecific binding, etc. Currently, the metabolic analysis of ^13^C‐glucose in the brain has received increasing attention.[3](#open201500196-bib-0003){ref-type="ref"} The present work shows a way to detect μ[m]{.smallcaps}‐level trace constituents and has shed light on the issues to be overcome for in vivo imaging. Further work is now underway along these lines with an ultimate goal of detection of hypodopaminergy in related diseases.

Experimental Section {#open201500196-sec-0002}
====================

1) General methods, 2) preparation, 3) monitoring of the [l]{.smallcaps}‐Dopa‐to‐dopamine conversion and subsequent dopamine oxidation, and 4) phantom MRS are included in the Supporting Information.
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